Rallybio Corp (RLYB): Revenue

Annual figures by period end, from SEC filings.

$858.0K

Year ended 2025-12-31

$646.0K

Trailing 12 months to 2026-06-30

2024-12-31 Revenue (USD) 2025-12-31

Period ended	Revenue	Change YoY	Source filing
2025-12-31	$858.0K	+34.9%	2026-03-16, From 2025-01-01
2024-12-31	$636.0K	n/a	2026-03-16, From 2024-01-01

Revenue at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

Company	Year ended	Revenue	Change YoY
Rallybio Corp (RLYB)	2025-12-31	$858.0K	+34.9%
Onconetix, Inc. (ONCO)	2025-12-31	$815.4K	-67.7%
Rafael Holdings, Inc. (RFL)	2025-07-31	$917.0K	+44.0%
Shattuck Labs, Inc. (STTK)	2025-12-31	$1.00M	-82.5%
60 Degrees Pharmaceuticals, Inc. (SXTP)	2025-12-31	$1.01M	+65.5%
Dare Bioscience, Inc. (DARE)	2025-12-31	$1.03M	n/m
Lexaria Bioscience Corp. (LEXX)	2025-08-31	$705.9K	+52.0%
Bespoke Extracts, Inc. (BSPK)	2024-12-31	$1.12M	+42.3%
Polomar Health Services, Inc. (PMHS)	2025-12-31	$648.2K	n/m

Compare RLYB, ONCO, RFL, STTK side by side · Screen every company in Pharmaceutical Preparations ↗